6 completed, 4 active not recruiting, 4 recruiting, 1 withdrawn. 9 Phase 1, 5 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 9 | Completed 6, Active not recruiting 1, Recruiting 1, Withdrawn 1 |
| Phase 2 | 5 | Active not recruiting 3, Recruiting 2 |
Follow Recurrent Lymphoma: new trials by email Literature Review of Recurrent Lymphoma trials Research Report on Recurrent Lymphoma
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Collecting Blood and Tissue Sample Donations for Research for HIV/AIDS-Related Cancers Biospecimen Collection - Anal Carcinoma, Hematopoietic and Lymphoid Cell Neoplasm | Recruiting | AIDS Malignancy Consortium | 200 | 2023-05-10 | 2026-06-01 | |
| CBL0137 for the Treatment of Relapsed or Refractory Solid Tumors, Including CNS Tumors and Lymphoma Biospecimen Collection, Bone Marrow Aspirate, Bone Marrow Biopsy - Diffuse Midline Glioma, H3 K27-Altered, Metastatic Malignant Neoplasm in the Central Nervous System | Phase 1 / Phase 2 | Recruiting | Children's Oncology Group | 63 | 2022-01-28 | 2026-09-11 |
| Elimusertib for the Treatment of Relapsed or Refractory Solid Tumors Elimusertib - Recurrent Alveolar Rhabdomyosarcoma, Recurrent Ewing Sarcoma | Phase 1 / Phase 2 | Active not recruiting | National Cancer Institute (NCI) | 31 | 2021-12-22 | 2026-01-23 |
| Frequency of Cachexia in Ambulatory Cancer Patients and Psychological Burden in Patients and Their Primary Caregivers Questionnaire Administration - Advanced Malignant Solid Neoplasm, Caregiver | Active not recruiting | M.D. Anderson Cancer Center | 192 | 2021-06-22 | 2026-08-06 | |
| Testing the Combination of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) in Children, Adolescent, and Young Adult Patients With Relapsed/Refractory Cancers That Have an Increased Number of Genetic Changes, The 3CI Study Biospecimen Collection, Ipilimumab, Nivolumab - Constitutional Mismatch Repair Deficiency Syndrome, Hematopoietic and Lymphoid Cell Neoplasm | Phase 1 | Withdrawn | National Cancer Institute (NCI) | 2021-05-11 | 2026-06-10 | |
| Selpercatinib for the Treatment of Advanced Solid Tumors, Lymphomas, or Histiocytic Disorders With Activating RET Gene Alterations, a Pediatric MATCH Treatment Trial Computed Tomography, Magnetic Resonance Imaging, Positron Emission Tomography - Hematopoietic and Lymphatic System Neoplasm, Recurrent Ependymoma | Phase 2 | Active not recruiting | National Cancer Institute (NCI) | 1 | 2021-05-03 | 2026-10-09 |
| Ascorbic Acid and Chemotherapy for the Treatment of Relapsed or Refractory Lymphoma, CCUS, and Chronic Myelomonocytic Leukemia Ascorbic Acid, Carboplatin, Cisplatin - Clonal Cytopenia of Undetermined Significance, High Grade B-Cell Lymphoma With MYC and BCL2 or BCL6 Rearrangements | Phase 2 | Recruiting | Mayo Clinic | 80 | 2018-03-23 | 2026-09-28 |
| Pevonedistat, Irinotecan, and Temozolomide in Treating Patients With Recurrent or Refractory Solid Tumors or Lymphoma Irinotecan, Pevonedistat, Temozolomide - Recurrent Lymphoma, Recurrent Malignant Solid Neoplasm | Phase 1 | Completed | Children's Oncology Group | 30 | 2018-01-11 | 2024-10-22 |
| IACS-010759 in Advanced Cancers Oxidative Phosphorylation Inhibitor IACS-010759, Pharmacodynamic Study, Pharmacokinetic Study - Advanced Malignant Solid Neoplasm, Anatomic Stage III Breast Cancer AJCC v8 | Phase 1 | Completed | M.D. Anderson Cancer Center | 29 | 2017-11-13 | 2020-11-24 |
| Trigriluzole With Nivolumab and Pembrolizumab in Treating Patients With Metastatic or Unresectable Solid Malignancies or Lymphoma Enzyme Inhibitor Therapy, Laboratory Biomarker Analysis, Nivolumab - Lymphoma, Metastatic Malignant Solid Neoplasm | Phase 1 | Completed | Rutgers, The State University of New Jersey | 14 | 2017-10-03 | 2023-12-06 |
| Entinostat in Treating Pediatric Patients With Recurrent or Refractory Solid Tumors Entinostat, Laboratory Biomarker Analysis, Pharmacological Study - Brain Stem Neoplasm, Pineal Region Neoplasm | Phase 1 | Completed | National Cancer Institute (NCI) | 21 | 2017-01-06 | 2023-10-17 |
| Selinexor in Treating Younger Patients With Recurrent or Refractory Solid Tumors or High-Grade Gliomas Pharmacological Study, Selinexor - Malignant Glioma, Recurrent Brain Neoplasm | Phase 1 | Completed | Children's Oncology Group | 59 | 2015-10-30 | 2025-01-14 |
| Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial) Adavosertib, Afatinib, Afatinib Dimaleate - Advanced Lymphoma, Advanced Malignant Solid Neoplasm | Phase 2 | Active not recruiting | National Cancer Institute (NCI) | 6452 | 2015-08-17 | 2026-10-22 |
| Vinblastine and Temsirolimus in Pediatrics With Recurrent or Refractory Lymphoma or Solid Tumours Including CNS Tumours Vinblastine, Temsirolimus - Recurrent Lymphoma, Refractory Lymphoma | Phase 1 | Completed | Canadian Cancer Trials Group | 7 | 2015-06-24 | 2023-08-04 |
| Effects of Dexrazoxane Hydrochloride on Biomarkers Associated With Cardiomyopathy and Heart Failure After Cancer Treatment Assessment of Therapy Complications, Laboratory Biomarker Analysis, Quality-of-Life Assessment - Hodgkin Lymphoma in Remission, Leukemia in Remission | Recruiting | Children's Oncology Group | 420 | 2014-03-05 | 2026-05-18 |
Lymphoma (15) · Central Nervous System Neoplasms (4) · Glioma (3) · Hematologic Neoplasms (3) · Neoplasm Metastasis (3) · Carcinoma, Renal Cell (2) · Leukemia (2) · Melanoma (2) · Multiple Myeloma (2) · Neuroblastoma (2) · Osteosarcoma (2) · Pancreatic Neoplasms (2) · Sarcoma, Ewing (2) · Urinary Bladder Neoplasms (2) · Anus Neoplasms (1)
Hemic and Lymphatic Diseases (15) · Immune System Diseases (15) · Immunoproliferative Disorders (15) · Lymphatic Diseases (15) · Lymphoproliferative Disorders (15) · Neoplasms (15) · Neoplasms by Histologic Type (15) · Neoplasms by Site (10) · Neoplasms, Germ Cell and Embryonal (7) · Neoplasms, Glandular and Epithelial (7) · Neoplasms, Nerve Tissue (7) · Neuroectodermal Tumors (7) · Hematologic Diseases (6) · Neoplasms, Neuroepithelial (6) · Nervous System Diseases (5)
Specimen Handling (4) · Biopsy (3) · Magnetic Resonance Spectroscopy (3) · Nivolumab (3) · X-Rays (3) · Nuclear Medicine Department, Hospital (2) · 1,2-diaminocyclohexaneplatinum II citrate (1) · 2-(3-(2-(1-isopropyl-3-methyl-1H-1,2-4-triazol-5-yl)-5,6-dihydrobenzo(f)imidazo(1,2-d)(1,4)oxazepin-9-yl)-1H-pyrazol-1-yl)-2-methylpropanamide (1) · 2C4 antibody (1) · AZD4547 (1) · Ado-Trastuzumab Emtansine (1) · Afatinib (1) · Ascorbic Acid (1) · BAY 1895344 (1) · Biopsy, Large-Core Needle (1)
National Cancer Institute (NCI) (5) · Children's Oncology Group (4) · M.D. Anderson Cancer Center (2) · AIDS Malignancy Consortium (1) · Canadian Cancer Trials Group (1) · Mayo Clinic (1) · Rutgers, The State University of New Jersey (1)
United States (14) · Canada (4) · Australia (3) · Puerto Rico (3) · Guam (1)
Andrea T Franson (1) · Andrew Bukowinski (1) · Biren Saraiya (1) · Daniel A Morgenstern (1) · David S Ziegler (1) · Eric J Chow (1) · Jeff Bethony (1) · Jennifer H Foster (1) · Julia Glade-Bender (1) · Keith T Flaherty (1) · Michael V Ortiz (1) · Rebecca Deyell (1) · Rony Dev (1) · Sylvain Baruchel (1) · Thomas E Witzig, M.D. (1)
PMID 26014292, PMID 26586415, PMID 30393943, PMID 32463741, PMID 33048619, PMID 34644414, PMID 34810210, PMID 35133871, PMID 35138919, PMID 35780243, PMID 36351402, PMID 36658425, PMID 36669148, PMID 37053535, PMID 37322121, PMID 37934000, PMID 38591867, PMID 39352751, PMID 39462179, PMID 39666929, PMID 39693587, PMID 39913886, PMID 39998852, PMID 40865033, PMID 41066729, PMID 42561216, PMID 42867148
UM1CA097452 (3), UM1CA228823 (2), P30CA015704 (1), P30CA016672 (1), P30CA072720 (1), P50CA097274 (1), R01CA211996 (1), U10CA095861 (1), U10CA180820 (1), U10CA180886 (1), U24CA196172 (1), UG1CA189955 (1), UM1CA121947 (1), UM1CA154967 (1)